Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.40 |
| ▸ | TNK1 | Q13470 | 5/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522872 | 0.91 | MAPT (0.43) | ADRA1BDRD4DRD2DRD3KDM4E | |
| SCHEMBL5530513 | 0.91 | MAPT (0.43) | PARP1TNK1TNK2ADRA1DADRA1A | |
| SCHEMBL5529004 | 0.87 | PARP1 (0.38) | PARP1TNK1TNK2ADRA1DADRA1A | |
| SCHEMBL5526799 | 0.85 | ALDH1A1 (0.46) | PARP1TNK1TNK2KDM4EHRH3 | |
| SCHEMBL5530846 | 0.85 | DRD2 (0.39) | PARP1PARP2DRD4DRD2DRD3 | |
| SCHEMBL5535139 | 0.79 | NPC1 (0.37) | PARP1GNRHRDRD4KDM4E | |
| SCHEMBL5531534 | 0.78 | PARP1 (0.43) | PARP1TNK1TNK2KDM4E | |
| SCHEMBL5528656 | 0.76 | KDM4E (0.49) | KDM4EHRH3 | |
| SCHEMBL5523950 | 0.76 | ALDH1A1 (0.49) | KDM4EHRH3 | |
| SCHEMBL5527313 | 0.75 | HRH3 (0.41) | PARP1TNK1TNK2PARP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | PARP1 435/4885TNK1 2730/4885TNK2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.